知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

2627 条记录 (耗时 0.032 秒)

    STABLE GLUCAGON ANALOGUES AND USE FOR TREATMENT OF HYPOGLYCAEMIA
    12.
    发明申请
    STABLE GLUCAGON ANALOGUES AND USE FOR TREATMENT OF HYPOGLYCAEMIA 有权
    稳定的GLUCAGON类似物和用于治疗高血糖症的用途

    公开(公告)号：US20170008943A1

    公开(公告)日：2017-01-12

    申请号：US15117993

    申请日：2015-02-18

    申请人： NOVO NORDISK A/S

    发明人： Jesper F. Lau ,  Thomas Kruse ,  Peter Kresten Nielsen

    IPC分类号： C07K14/605 ,  C07K19/00

    CPC分类号： C07K14/605 ,  A61K38/00 ,  C07K19/00

    摘要： The invention relates to derivatives of glucagon analogues comprising the substitutions Imp1 and His3, a substituent having three to ten negatively charged moieties covalently attached to a side chain of a lysine as well as intermediates and compositions thereof and their use in medicine.

    摘要翻译： 本发明涉及胰高血糖素类似物的衍生物，其包含取代基Imp1和His3，具有共价连接到赖氨酸侧链上的三至十个带负电荷的基团的取代基，以及其中间体及其组合物及其在药物中的用途。

    Medical device with actuation mechanism
    13.
    发明授权
    Medical device with actuation mechanism 有权

    公开(公告)号：US12121688B2

    公开(公告)日：2024-10-22

    申请号：US17426848

    申请日：2020-01-31

    申请人： Novo Nordisk A/S

    发明人： Brian Jensen ,  Morten Revsgaard Frederiksen ,  Brian Mouridsen ,  Jacob Pyung Hwa Jepsen

    IPC分类号： A61M37/00 ,  A61M31/00

    CPC分类号： A61M37/0069 ,  A61M31/002 ,  A61M2210/1053 ,  A61M2210/106 ,  A61M2210/1064

    摘要： A medical delivery device suitable for insertion into a lumen of a patient, the medical device (100, 200) comprising a capsule (110, 120, 210, 220) sized to be inserted into the lumen, the capsule comprising a base member, and an actuation mechanism comprising an actuation member (150, 250, 350) configured for movement relative to the base member along an axis, and an energy source (140, 240, 340) associated with the actuation member for powering the actuation member to move relative to the base member along the axis. The base member and the actuation member define a latch assembly comprising: a) a dissolvable firing member (160, 260, 360), the dissolvable firing member being at least partially dissolvable when subjected to a biological fluid, b) a retainer portion (113, 213, 313) comprised by one of the base member and the actuation member, and c) a movable latch (152, 252, 352) configured for lateral movement relative to the axis, the movable latch defining a first surface with a blocking portion (153, 253, 353), and a second surface (152a, 252a, 352a) configured for interacting with the dissolvable firing member (160, 260, 360). In a pre-firing configuration, the blocking portion (153, 253, 353) of the movable latch engages the retainer portion (113, 213, 313) in a latching engagement, and the second surface (152a, 252a, 352a) of the movable latch interacts with the dissolvable firing member to restrict lateral movement of the movable latch thereby preventing release of the latching engagement. In a firing configuration where the dissolvable firing member (160, 260) has become at least partially dissolved, the movable latch is allowed to move laterally thereby releasing the latching engagement.

    Drug delivery device with dose counting mechanism
    14.
    发明授权
    Drug delivery device with dose counting mechanism 有权

    公开(公告)号：US12115358B2

    公开(公告)日：2024-10-15

    申请号：US16981328

    申请日：2019-03-22

    申请人： Novo Nordisk A/S

    发明人： Nicolai Michael Jensen ,  Klaus Bendix

    IPC分类号： A61M5/315 ,  A61M5/20 ,  A61M5/31 ,  A61M5/32

    CPC分类号： A61M5/31595 ,  A61M5/2033 ,  A61M5/31526 ,  A61M5/3202 ,  A61M2005/3126

    摘要： A drug delivery device includes a dose counting mechanism and an end-of-content or remaining-dose indication. For example, a dose expelling mechanism is coupled to a reciprocating element configured to undergo a predefined motion during each dose expelling action to allow a dose to be expelled. The predefined motion includes displacement in a first axial direction from a first position to a second position followed by displacement in a second axial direction from the second position to the first position, with a counter element being movable in the first axial direction. First and second unidirectional ratchet mechanisms prevent motion in the first axial direction and allow motion in the second axial direction of the reciprocating element relative to the counter element, and vice versa, respectively.

    MEDICAL DEVICE WITH FLUID ACIVATED ACTUATION MECHANISM
    16.
    发明公开
    MEDICAL DEVICE WITH FLUID ACIVATED ACTUATION MECHANISM 审中-公开

    公开(公告)号：US20240252796A1

    公开(公告)日：2024-08-01

    申请号：US18566555

    申请日：2022-06-09

    申请人： Novo Nordisk A/S

    发明人： Noekkvi Steinn Sigurdarson

    IPC分类号： A61M31/00

    CPC分类号： A61M31/002

    摘要： A self-righting ingestible capsule comprising: a) a capsule housing (110, 120) defining a central axis and having proximal and distal ends, b) a sealing compartment (A) within the capsule housing (110, 120) accommodating a solid dose member (130), and comprising a distal exit port (124), c) an actuation compartment (B) fluidically isolated from the scaling compartment (A), d) an actuation member (150) at least partially accommodated in the actuation compartment (B) and arranged for axial displacement thereby moving the dose member (130) distally through the distal exit port (124), e) a helical spring (140) for powering the actuation member (150) in a distal direction, f) a latch component (152) coupled to the actuation member (150) for releasably maintaining the actuation member latched in a proximal position, and g) a dissolvable latch support (160) disposed in the actuation compartment (B), wherein the dissolvable latch support maintains latching of the actuation member (150) in the proximal position by supporting the latch component

    INSULIN ON BOARD FOR GLUCOSE SENSITIVE INSULIN
    17.
    发明公开
    INSULIN ON BOARD FOR GLUCOSE SENSITIVE INSULIN 审中-公开

    公开(公告)号：US20240242810A1

    公开(公告)日：2024-07-18

    申请号：US18289294

    申请日：2022-05-05

    申请人： Novo Nordisk A/S

    发明人： Henrik Bengtsson ,  Tinna Bjoerk Aradottir ,  Sarah Ellinor Engell ,  Thomas Emil Ryde

    IPC分类号： G16H20/17

    CPC分类号： G16H20/17

    摘要： A method of estimating insulin on board (IOB) for a given glucose sensitive insulin (GSI) in a subject is provided. The method comprises the steps (i) for the given GSI, providing at least one rate constant (rc) as function of glucose concentration (rc(G)), (ii) providing for a period of time a continuous blood glucose log G(t) from the subject, (iii) providing for the period of time 5 an insulin dose log I(t) from the subject, (iv) based on rc(G) and G(t), calculating for each rc a rate constant as function of time (rc(t)), and (v) based on the at least one rc(t) and I(t) and using an estimating algorithm, calculating an estimated IOB for the subject.